Back to Agendas
CBER Town Hall: Innovation and Public Health Response
Session Chair(s)
Karen Midthun, MD
Principal, Drug and Biological Products, Greenleaf Health, United States
Join us for this unique opportunity that includes members from Center for Biologics Evaluation and Research’s (CBER) leadership for an overview of CBER’s regulatory programs, including efforts related to expedited review, regulatory science, and postmarketing surveillance. We will discuss how the Center has used expedited programs in response to public health issues and how it facilitates the development of innovative products. Attendees are welcome to submit questions to the panel by emailing annualmeetingprogram@diaglobal.org; subject line: CBER Town Hall Q/A.
Learning Objective : Summarize key issues discussed by CBER; Identify regulatory hot topics in biologics.
Speaker(s)
Panelist
Theresa M. Finn, PhD
Associate Director for Regulatory Policy, OVRR, CBER , FDA, United States
Panelist
Wilson W. Bryan, MD
Executive Vice President, Drug and Biological Products, Greenleaf Health, United States
Panelist
Steven A. Anderson, PhD
Director, Office of Biostatistics and Epidemiology, CBER, FDA, United States
Have an account?